Urinary Vitamin D Binding Protein: A Potential Novel Marker of Renal Interstitial Inflammation and Fibrosis

PLoS ONE

Volumn 8, Issue 2, 2013, Pages

  Mirković, Katarina ^a   Doorenbos, Carolina R C ^a   Dam, Wendy A ^a   Lambers Heerspink, Hiddo J ^a   Slagman, Maartje C J ^a   Nauta, Ferdau L ^a   Kramer, Andrea B ^a   Gansevoort, Ronald T ^a   van den Born, Jacob ^a   Navis, Gerjan ^a   de Borst, Martin H ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; BETA 2 MICROGLOBULIN; COLLAGEN TYPE 3; CYSTATIN C; KIDNEY INJURY MOLECULE 1 PROTEIN; MEMBRANE PROTEIN; MONOCYTE CHEMOTACTIC PROTEIN 1; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; UNCLASSIFIED DRUG; VITAMIN D BINDING PROTEIN;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOACCUMULATION; BLOOD LEVEL; BLOOD SAMPLING; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE MARKER; HUMAN; INTERSTITIAL NEPHRITIS; KIDNEY FIBROSIS; MACROPHAGE; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; MOLECULAR DYNAMICS; NONHUMAN; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEINURIA; RAT; URINALYSIS; URINARY EXCRETION; URINE LEVEL;

ALBUMINURIA; ANIMALS; BIOLOGICAL MARKERS; DISEASE MODELS, ANIMAL; DOXORUBICIN; FIBROSIS; HUMANS; KIDNEY; MALE; NEPHRITIS, INTERSTITIAL; PROTEINURIA; RATS; VITAMIN D-BINDING PROTEIN;

EID: 84873714984     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0055887     Document Type: Article

References (23)

1. Liu Y, (2011) Cellular and molecular mechanisms of renal fibrosis. Nat Rev Nephrol 7: 684-696.
2. Remuzzi G, Benigni A, Remuzzi A, (2006) Mechanisms of progression and regression of renal lesions of chronic nephropathies and diabetes. J Clin Invest 116: 288-296.
3. Perico N, Cattaneo D, Remuzzi G, (2009) Kidney injury molecule 1: In search of biomarkers of chronic tubulointerstitial damage and disease progression. Am J Kidney Dis 53: 1-4.
4. Verboven C, Rabijns A, De Maeyer M, Van Baelen H, Bouillon R, et al. (2002) A structural basis for the unique binding features of the human vitamin D-binding protein. Nat Struct Biol 9: 131-136.
5. Nykjaer A, Dragun D, Walther D, Vorum H, Jacobsen C, et al. (1999) An endocytic pathway essential for renal uptake and activation of the steroid 25-(OH) vitamin D3. Cell 96: 507-515.
6. Leheste JR, Rolinski B, Vorum H, Hilpert J, Nykjaer A, et al. (1999) Megalin knockout mice as an animal model of low molecular weight proteinuria. Am J Pathol 155: 1361-1370.
7. Nykjaer A, Fyfe JC, Kozyraki R, Leheste JR, Jacobsen C, et al. (2001) Cubilin dysfunction causes abnormal metabolism of the steroid hormone 25(OH) vitamin D(3). Proc Natl Acad Sci U S A 98: 13895-13900.
8. Doorenbos CR, van den Born J, Navis G, de Borst MH, (2009) Possible renoprotection by vitamin D in chronic renal disease: Beyond mineral metabolism. Nat Rev Nephrol 5: 691-700.
9. Doorenbos CR, de Cuba MM, Vogt L, Kema IP, van den Born J, et al. (2012) Antiproteinuric treatment reduces urinary loss of vitamin D-binding protein but does not affect vitamin D status in patients with chronic kidney disease. J Steroid Biochem Mol Biol 128: 56-61.
10. Thrailkill KM, Jo CH, Cockrell GE, Moreau CS, Fowlkes JL, (2011) Enhanced excretion of vitamin D binding protein in type 1 diabetes: A role in vitamin D deficiency? J Clin Endocrinol Metab 96: 142-149.
11. Kramer AB, Ricardo SD, Kelly DJ, Waanders F, van Goor H, et al. (2005) Modulation of osteopontin in proteinuria-induced renal interstitial fibrosis. J Pathol 207: 483-492.
12. Bertani T, Cutillo F, Zoja C, Broggini M, Remuzzi G, (1986) Tubulo-interstitial lesions mediate renal damage in adriamycin glomerulopathy. Kidney Int 30: 488-496.
13. Pinto-Sietsma SJ, Janssen WM, Hillege HL, Navis G, De Zeeuw D, et al. (2000) Urinary albumin excretion is associated with renal functional abnormalities in a nondiabetic population. J Am Soc Nephrol 11: 1882-1888.
14. Slagman MC, Waanders F, Hemmelder MH, Woittiez AJ, Janssen WM, et al. (2011) Moderate dietary sodium restriction added to angiotensin converting enzyme inhibition compared with dual blockade in lowering proteinuria and blood pressure: Randomised controlled trial. BMJ 343: d4366.
15. Nauta FL, Boertien WE, Bakker SJ, van Goor H, van Oeveren W, et al. (2011) Glomerular and tubular damage markers are elevated in patients with diabetes. Diabetes Care 34: 975-981.
16. de Borst MH, Nauta FL, Vogt L, Laverman GD, Gansevoort RT, et al. (2012) Indomethacin reduces glomerular and tubular damage markers but not renal inflammation in chronic kidney disease patients: A post-hoc analysis. PLoS One 7: e37957.
17. Kramer AB, Laverman GD, van Goor H, Navis G, (2003) Inter-individual differences in anti-proteinuric response to ACEi in established adriamycin nephrotic rats are predicted by pretreatment renal damage. J Pathol 201: 160-167.
18. De Boer E, Navis G, Tiebosch AT, De Jong PE, De Zeeuw D, (1999) Systemic factors are involved in the pathogenesis of proteinuria-induced glomerulosclerosis in adriamycin nephrotic rats. J Am Soc Nephrol 10: 2359-2366.
19. Malard V, Gaillard JC, Berenguer F, Sage N, Quemeneur E, (2009) Urine proteomic profiling of uranium nephrotoxicity. Biochim Biophys Acta 1794: 882-891.
20. Gekle M, Knaus P, Nielsen R, Mildenberger S, Freudinger R, et al. (2003) Transforming growth factor-beta1 reduces megalin- and cubilin-mediated endocytosis of albumin in proximal-tubule-derived opossum kidney cells. J Physiol 552: 471-481.
21. Hosojima M, Sato H, Yamamoto K, Kaseda R, Soma T, et al. (2009) Regulation of megalin expression in cultured proximal tubule cells by angiotensin II type 1A receptor- and insulin-mediated signaling cross talk. Endocrinology 150: 871-878.
22. Hamming I, Navis G, Kocks MJ, van Goor H, (2006) ACE inhibition has adverse renal effects during dietary sodium restriction in proteinuric and healthy rats. J Pathol 209: 129-139.
23. Vegter S, Perna A, Postma MJ, Navis G, Remuzzi G, et al. (2012) Sodium intake, ACE inhibition, and progression to ESRD. J Am Soc Nephrol 23: 165-173.